Answers are grounded in this paper and cite their sources.
Background Transdermal drug delivery offers a minimally invasive and patient-friendly alternative to conventional administration routes; however, the stratum corneum (SC) acts as a substantial barrier, reducing the permeation of therapeutics, specifically macromolecules, and consequently limiting their bioavailability. Three main approaches have been investigated for bypassing the SC and delivering therapeutics, such as employing physical techniques ( e.g., microneedles (MNs)), nanotechnology-based techniques ( e.g., nanoparticles (NPs), liposomes, and micelles), and chemical methods ( e.g., fatty acids). MNs overcome this barrier by creating temporary microchannels across the SC with minimal tissue damage and pain, while NPs such as micelles and liposomes can improve therapeutics solubilization, encapsulation, stability, and transport. Combining these two technologies therefore provides a rational strategy to overcome the individual limitations of MNs and NP-based delivery systems. Technology The synergistic approach integrates the physical barrier-bypassing capability of MNs with the therapeutic encapsulation capabilities of micelles or liposomes. MNs, including solid, coated, dissolving, hollow, and hydrogel, can transiently disrupt the SC and provide direct route for NPs to transport into the deeper layers. Meanwhile, micelles are particularly advantageous for encapsulating poorly water-soluble small molecules, whereas liposomes can accommodate both hydrophilic and hydrophobic therapeutics and offer greater flexibility for the delivery of larger or more complex payloads. The unmet clinical need for minimally invasive, efficient, and patient-friendly delivery systems has driven increasing interest in integrating complementary technologies to overcome the limitations of conventional delivery approaches. Results Integration of micelles and liposomes with MNs can enhance therapeutic delivery, bioavailability, and stability, while offering opportunities for controlled and co-delivery of multiple therapeutic agents. Dissolving MNs, particularly liposome-loaded systems, have shown the most promising results to date. However, limited in vivo evidence, the absence of clinical trials, and unresolved long-term safety, manufacturing, and regulatory challenges remain major barriers to clinical translation.
No takes yet. Share an insight, caveat, or question.
Khosrowshahi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: